bioRxivBiochemistry
High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector.
M. V. Sinegubova, N. A. Orlova, S. V. Kovnir, L. K. Dayanova, I. I. Vorobiev
Abstract
The spike (S) protein is one of the three proteins forming the coronaviruses viral envelope. The S protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has a spatial structure similar to the S proteins of other mammalian coronaviruses, except for a unique receptor-binding domain (RBD), which is a significant inducer of host immune response. Recombinant SARS-CoV-2 RBD is widely used as a highly specific minimal antigen for serological tests. Correct exposure of antigenic determinants has a significant impact on the accuracy of such tests - the antigen has to be correctly folded, contain no potentially antigenic non-vertebrate glycans, and, preferably, should have a glycosylation pattern similar to the native S protein. Based on the previously developed p1.1 vector, containing the regulatory sequences of the Eukaryotic translation elongation factor 1 alpha gene (EEF1A1) from Chinese hamster, we created two expression constructs encoding SARS-CoV-2 RBD with C-terminal c-myc and polyhistidine tags. RBDv1 contained a native viral signal peptide, RBDv2 - human tPA signal peptide. We transfected a CHO DG44 cell line, selected stably transfected cells, and performed a few rounds of methotrexate-driven amplification of the genetic cassette in the genome. For the RBDv2 variant, a high-yield clonal producer cell line was obtained. We developed a simple purification scheme that consistently yielded up to 30 mg of RBD protein per liter of the simple shake flask cell culture. Purified proteins were analyzed by polyacrylamide gel electrophoresis in reducing and non-reducing conditions and gel filtration; for RBDv2 protein, the monomeric form content exceeded 90% for several series. Deglycosylation with PNGase F and mass spectrometry confirmed the presence of N-glycosylation. The antigen produced by the described technique is suitable for serological tests and similar applications.
- organism: mouse
- assay: proteomics
- research focus: protein folding & dynamics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
J. Mehalko, M. Drew, … D. Esposito·bioRxiv·Nov 18, 2020
- Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells
C. Gstoettner, T. Zhang, … E. Dominguez-Vega·bioRxiv·Feb 23, 2021
- Development and characterization of a multimeric recombinant protein based on the spike protein receptor binding domain of SARS-CoV-2 that can neutralize virus infection
V. A. de Lima, R. d. S. Ferreira, … S. Schenkman·bioRxiv·Feb 15, 2023
- The nuts and bolts of SARS-CoV-2 Spike Receptor Binding Domain heterologous expression
M. Maffei, L. C. Montemiglio, … E. Marra·bioRxiv·Sep 17, 2021
- Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay
K. L. Tee, P. J. Jackson, … T. S. Wong·bioRxiv·Jul 31, 2020
- An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines
B. D. Quinlan, W. Li, … M. Farzan·bioRxiv·Nov 18, 2020